The Goldman Sachs Group Lowers Humana (NYSE:HUM) Price Target to $158.00

Humana (NYSE:HUM) had its price target dropped by investment analysts at The Goldman Sachs Group from $215.00 to $158.00 in a report issued on Friday,MarketScreener reports. The brokerage currently has a “sell” rating on the insurance provider’s stock. The Goldman Sachs Group’s price target would suggest a potential downside of 14.09% from the company’s previous close.

A number of other equities research analysts have also recently issued reports on the stock. JPMorgan Chase & Co. reduced their target price on shares of Humana from $274.00 to $180.00 and set a “neutral” rating for the company in a research report on Friday. Deutsche Bank Aktiengesellschaft set a $180.00 target price on shares of Humana and gave the stock a “hold” rating in a research report on Friday. TD Cowen lowered their target price on shares of Humana from $260.00 to $173.00 and set a “hold” rating on the stock in a report on Friday. Jefferies Financial Group cut their price target on Humana from $310.00 to $235.00 and set a “buy” rating for the company in a research note on Thursday. Finally, Barclays restated an “underperformer” rating on shares of Humana in a research note on Monday, January 5th. Seven equities research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and five have issued a Sell rating to the company’s stock. According to data from MarketBeat, Humana presently has a consensus rating of “Hold” and an average target price of $238.29.

Humana Trading Up 2.8%

Shares of HUM stock opened at $183.92 on Friday. Humana has a 12-month low of $169.61 and a 12-month high of $315.35. The company has a market capitalization of $22.12 billion, a PE ratio of 18.73, a price-to-earnings-growth ratio of 2.04 and a beta of 0.44. The firm has a 50 day moving average price of $244.65 and a two-hundred day moving average price of $261.05. The company has a quick ratio of 2.02, a current ratio of 2.00 and a debt-to-equity ratio of 0.70.

Humana (NYSE:HUM) last announced its earnings results on Wednesday, February 11th. The insurance provider reported ($3.96) earnings per share for the quarter, topping analysts’ consensus estimates of ($4.01) by $0.05. The company had revenue of $32.64 billion for the quarter, compared to analyst estimates of $32.08 billion. Humana had a return on equity of 11.43% and a net margin of 0.92%.The firm’s quarterly revenue was up 11.3% compared to the same quarter last year. During the same quarter last year, the company earned ($2.16) earnings per share. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. As a group, analysts predict that Humana will post 16.47 earnings per share for the current year.

Institutional Investors Weigh In On Humana

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Sound View Wealth Advisors Group LLC increased its stake in shares of Humana by 3.5% in the 4th quarter. Sound View Wealth Advisors Group LLC now owns 1,060 shares of the insurance provider’s stock valued at $272,000 after purchasing an additional 36 shares during the last quarter. Unison Advisors LLC boosted its stake in Humana by 0.4% in the third quarter. Unison Advisors LLC now owns 10,137 shares of the insurance provider’s stock valued at $2,646,000 after buying an additional 37 shares in the last quarter. CoreCap Advisors LLC grew its position in Humana by 54.4% in the fourth quarter. CoreCap Advisors LLC now owns 105 shares of the insurance provider’s stock valued at $27,000 after acquiring an additional 37 shares during the last quarter. Insigneo Advisory Services LLC grew its position in Humana by 3.0% in the third quarter. Insigneo Advisory Services LLC now owns 1,484 shares of the insurance provider’s stock valued at $386,000 after acquiring an additional 43 shares during the last quarter. Finally, Columbus Macro LLC lifted its holdings in shares of Humana by 5.5% in the fourth quarter. Columbus Macro LLC now owns 821 shares of the insurance provider’s stock worth $210,000 after acquiring an additional 43 shares during the last quarter. 92.38% of the stock is currently owned by institutional investors.

Trending Headlines about Humana

Here are the key news stories impacting Humana this week:

• Positive Sentiment: CenterWell (Humana’s healthcare services unit) closed the acquisition of MaxHealth, adding a sizable Florida primary‑care network (~82 owned/affiliated clinics and >80,000 patients in value‑based programs) which expands Humana’s senior-focused, value‑based primary care footprint and accelerates revenue and membership growth in higher-value care. CenterWell Completes Acquisition of MaxHealth
• Positive Sentiment: Management signals more primary‑care deals may be coming (CEO remarks and media reports about a potential ~$1B strategic push), reinforcing the company’s strategy to grow value‑based care capacity — a long‑term growth catalyst if Humana can scale clinics and convert MA members to higher‑margin care. Humana CEO hints at upcoming primary care deal
• Neutral Sentiment: Jefferies cut its price target (from $310 to $235) but kept a Buy rating, reflecting disagreement among analysts on Humana’s growth vs. margin tradeoff — some firms still see upside despite lower near‑term earnings visibility. Jefferies price target change
• Negative Sentiment: Several major analysts materially lowered price targets and trimmed estimates (TD Cowen to $173 Hold; JPMorgan to $180 Neutral; Evercore, Cantor, Leerink also cut targets), reflecting concern that Medicare Advantage cost pressures, lower quality (STAR) ratings, and a cautious 2026 earnings guide will weigh on near‑term profitability. TD Cowen PT cut
• Negative Sentiment: Humana reported a fourth‑quarter loss and issued a cautious 2026 outlook (management flagged sharply lower near‑term earnings as Medicare Advantage membership surges but margins remain under pressure), which prompted analysts to slash forecasts and is the primary fundamental reason for downward pressure on the stock. Humana stock falls on disappointing earnings forecast

About Humana

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.